New drug combo aims to stop breast Cancer's comeback
NCT ID NCT03285412
Summary
This study is testing whether adding a drug called ribociclib to standard hormone therapy can better prevent early-stage, hormone-sensitive breast cancer from returning. It is for patients who have completed initial surgery and have a specific marker of very low-level cancer in their blood. The goal is to see if this combination treatment can clear this marker and improve long-term outcomes compared to hormone therapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Mass General/North Shore Cancer Center
Danvers, Massachusetts, 01923, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.